Figure 7
Cytolytic pathways and cytokine expression profile of the T-cell clones. (A) Flow cytometry analysis showing the expression of FasL, granzyme B, perforin, CD45RA, and CD45RO by the P66v-specific T-cell clone. HLA-A*0201-P66v-tetramer staining was used as control. (B) Intracellular cytokine staining showing the percentages of IFN-γ and IL-4–expressing CD8+ T cells in the P66v-specific T-cell clone after restimulation with unpulsed DCs or DCs pulsed with P66v peptide (P66v-DC). (C) ELISPOT assay showing the numbers of IFN-γ–secreting cells per 104 T cells in P20-specific (T16) or P66v-specific (T6) T-cell clones induced by unpulsed DCs (DC-control), DCs pulsed with P20 (DC-P20) or P66v (DC-P66v), HMCLs (U266 and ARP-1), or primary myeloma cells from 4 patients with MM (MM1-MM4). Figures represent the numbers of spots. Representative results of 4 experiments are shown. Similar results were obtained with other T-cell clones from blood donors and patients with myeloma.

Cytolytic pathways and cytokine expression profile of the T-cell clones. (A) Flow cytometry analysis showing the expression of FasL, granzyme B, perforin, CD45RA, and CD45RO by the P66v-specific T-cell clone. HLA-A*0201-P66v-tetramer staining was used as control. (B) Intracellular cytokine staining showing the percentages of IFN-γ and IL-4–expressing CD8+ T cells in the P66v-specific T-cell clone after restimulation with unpulsed DCs or DCs pulsed with P66v peptide (P66v-DC). (C) ELISPOT assay showing the numbers of IFN-γ–secreting cells per 104 T cells in P20-specific (T16) or P66v-specific (T6) T-cell clones induced by unpulsed DCs (DC-control), DCs pulsed with P20 (DC-P20) or P66v (DC-P66v), HMCLs (U266 and ARP-1), or primary myeloma cells from 4 patients with MM (MM1-MM4). Figures represent the numbers of spots. Representative results of 4 experiments are shown. Similar results were obtained with other T-cell clones from blood donors and patients with myeloma.

Close Modal

or Create an Account

Close Modal
Close Modal